Holen Sie sich die Stockscreener-App
257.38
3.55%
8.83
Handel nachbörslich:
257.38
Schlusskurs vom Vortag:
$248.55
Offen:
$249.4
24-Stunden-Volumen:
580.38K
Relative Volume:
1.16
Marktkapitalisierung:
$10.04B
Einnahmen:
$1.24B
Nettoeinkommen (Verlust:
$42.23M
KGV:
242.81
EPS:
1.06
Netto-Cashflow:
$150.33M
1W Leistung:
+7.25%
1M Leistung:
+8.17%
6M Leistung:
-5.68%
1J Leistung:
+37.68%
1-Tages-Spanne:
$247.34
$260.22
1-Wochen-Bereich:
$236.66
$260.22
52-Wochen-Spanne:
$181.13
$310.00
Penumbra Inc Stock (PEN) Company Profile
Firmenname
Penumbra Inc
Sektor
Branche
Telefon
(510) 995-2486
Adresse
ONE PENUMBRA PLACE, ALAMEDA, CA
Vergleichen Sie PEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
257.38 | 9.69B | 1.24B | 42.23M | 150.33M | 1.06 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-14 | Eingeleitet | BofA Securities | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-11 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | Eingeleitet | Stifel | Buy |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-31 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-07-31 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-29 | Herabstufung | Needham | Buy → Hold |
| 2023-01-30 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-10-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-09-09 | Hochstufung | Needham | Hold → Buy |
| 2022-07-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-04-19 | Eingeleitet | Deutsche Bank | Buy |
| 2022-03-08 | Eingeleitet | Needham | Hold |
| 2021-09-16 | Eingeleitet | Truist | Buy |
| 2021-06-04 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-12-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-10-07 | Fortgesetzt | Canaccord Genuity | Buy |
| 2020-09-29 | Eingeleitet | BTIG Research | Buy |
| 2020-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-05-21 | Eingeleitet | William Blair | Outperform |
| 2018-10-29 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-10-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-02-21 | Eingeleitet | William Blair | Outperform |
| 2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-13 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Penumbra Inc Aktie (PEN) Neueste Nachrichten
Penumbra, STAAR Surgical, CONMED, Acadia Healthcare, and Select Medical Shares Are Soaring, What You Need To Know | FinancialContent - FinancialContent
5 Insightful Analyst Questions From Penumbra’s Q2 Earnings Call - Yahoo Finance
PEN Q2 Deep Dive: Sales Force Expansion and Clinical Milestones Drive Outperformance - ca.finance.yahoo.com
Penumbra, STAAR Surgical, CONMED, Acadia Healthcare, and Select Medical Shares Are Soaring, What You Need To Know - Barchart.com
Penumbra Inc. Breaks Losing Streak — Is the Trend ReversingWeekly Chart Analysis With Entry Advice Provided - metal.it
Aspiration Thrombectomy Device Market Set to Witness - openPR.com
What makes Penumbra Inc. stock price move sharplyEarly Entry Picks Before News Breakout Reviewed - metal.it
Penumbra Inc.: Thrombectomy Business Expansion As a Significant Driver For Overall Market Share Growth! - Smartkarma
MACD Signals Flash Warning for Penumbra Inc. StockOptimized Watchlist With Daily Adjustments Launched - metal.it
How volatile is Penumbra Inc. stock compared to the marketAchieve breakthrough growth with proven strategies - Jammu Links News
Is it the right time to buy Penumbra Inc. stockBreakthrough profits - Jammu Links News
What are analysts’ price targets for Penumbra Inc. in the next 12 monthsRapid return acceleration - Jammu Links News
How strong is Penumbra Inc. company’s balance sheetFree Bull & Bear Market Updates - Jammu Links News
Is Penumbra Inc. a growth stock or a value stockAccelerated capital growth - Jammu Links News
Penumbra Inc. Stock Analysis and ForecastInvest smarter with real-time trading alerts - Jammu Links News
What are the latest earnings results for Penumbra Inc.Spectacular growth rates - Jammu Links News
What is the risk reward ratio of investing in Penumbra Inc. stockDiscover investment plans that deliver results - Jammu Links News
What are Penumbra Inc. company’s key revenue driversRapid portfolio appreciation - Jammu Links News
What institutional investors are buying Penumbra Inc. stockFree Risk Assessment Services - Jammu Links News
Results: Penumbra, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Penumbra, Inc. Reports Second Quarter 2025 Financial Results - ADVFN Brasil
Penumbra price target raised to $325 from $316 at Baird - TipRanks
Penumbra's Strong Growth Potential and Strategic Developments Support Buy Rating with $327 Price Target - AInvest
UBS Analyst Increases Penumbra's Price Target to $335 - AInvest
Penumbra to Present at Canaccord Genuity 45th Annual Growth Conference - AInvest
Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference - Eastern Progress
Morgan Stanley Raises Price Target for Penumbra (PEN) to $266 | - GuruFocus
Should You Invest in Penumbra (PEN)? - Insider Monkey
Penumbra, Inc. (NYSE:PEN) Q2 2025 Earnings Call Transcript - Insider Monkey
Penumbra Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Penumbra outlines 13% to 15% revenue growth target for 2025 as thrombectomy adoption accelerates - MSN
Penumbra Inc. Reports Strong Q2 Earnings with Growth in U.S. Thrombectomy - TipRanks
Penumbra Surges 11.9% on Q2 Earnings Beat and Margin Expansion as $300M Volume Pushes It to 407th Trading Rank - AInvest
Penumbra (PEN) Q2 Revenue Jumps 13% - AOL.com
Penumbra (PEN) Shares Skyrocket, What You Need To Know - Yahoo Finance
Penumbra stock price target lowered to $325 at RBC Capital on margin outlook - Investing.com India
Penumbra: Truist Securities maintains a 'Buy' Rating, The Target Price is $310 - AInvest
Penumbra (PEN) Analyst Rating Update: Baird Raises Price Target - GuruFocus
Penumbra (PEN) Price Target Revised by RBC Capital | PEN Stock N - GuruFocus
Penumbra (PEN) Price Target Raised by Truist Following Earnings Beat - GuruFocus
Penumbra stock price target raised to $335 from $330 at UBS on solid growth - Investing.com
Penumbra (PEN) Price Target Raised by Baird to $285 - GuruFocus
Penumbra (PEN) Target Price Raised by Canaccord Genuity | PEN St - GuruFocus
Penumbra price target raised to $335 from $330 at UBS - TipRanks
Why Did Penumbra Stock Soar 14.46%? - AInvest
S&P 500 Futures Climb in Premarket Trading; Penumbra, Marvell Technology Lead - Barron's
Why Penumbra Inc. stock attracts strong analyst attentionScalable Portfolio Growth Suggestions Released - metal.it
Penumbra Inc (PEN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Penumbra Inc (PEN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Penumbra Inc earnings beat by $0.03, revenue topped estimates - Investing.com Australia
Penumbra Inc (PEN) Q2 2025 Earnings Call Highlights: Strong Reve - GuruFocus
Finanzdaten der Penumbra Inc-Aktie (PEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):